Horizon Europe European Union
Neutral-Atom Platform Technologies
This action aims to establish European leadership in neutral-atom quantum simulation and digital quantum computing by delivering: • Fully programmable industry-ready quan…
Horizon Europe · European Union
Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
Opens 3 Jun 2027
The EU's Horizon Europe programme expects to make 4 awards of €10 million – €12 million each, from a total budget of €39.3 million. Applications close on 16 Sep 2027 (EU calls usually close at 17:00 Brussels time). Organisations in EU member states and Horizon Europe associated countries such as Türkiye can usually take part; the topic conditions control.
- Deadline
- 16 Sep 2027 (in 305 days)
- Opens
- 3 Jun 2027
- Grant amount
- €10 million – €12 million per project
- Total budget
- €39.3 million
- Funding rate
- 100% of eligible costs Standard rule for this programme; the call can differ.
- Total budget
- €39.3 million
- Expected awards
- 4
- Type of action
- HORIZON Research and Innovation Actions · HORIZON Action Grant Budget-Based
- Likely applicant types
- Companies, SMEs / start-ups, Non-profits, Universities & research, Public bodies From source categories or programme rules; the call decides.
- Funder
- Horizon Europe (HORIZON)
- Reference
- HORIZON-HLTH-2027-03-TOOL-04
- Call
- HORIZON-HLTH-2027-03
- Last checked
- 14 Nov 2026
Expected outcome
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
• Healthcare professionals have access to multi-scale [1] , multi-organ models of individual patients that aim to improve prevention and diagnosis in high disease burden areas.
• Health professionals benefit from enhanced knowledge of complex diseases and co-morbidities by recourse to multi-scale, multi-organ models.
• Patients with diverse characteristics (e.g. of any sex, age group, racial or ethnic origin [2] ) benefit from improved, integrated and personalised prevention and diagnostics tools.
• Health professionals and patients benefit from the use of “Virtual Human Twin” (VHT) models which enable integration of other preventive and diagnostic tools and modalities.
Scope
VHTs are digital representations and in-silico models of an individual’s health and disease state at different levels of anatomy. Multi-scale, multi-organ VHT solutions have a potential for tailored prevention and diagnosis, particularly in areas of high disease burden, and can significantly benefit citizens' health and the efficiency of EU health systems.
Proposals should take into account the work of projects funded under topic HORIZON-HLTH-2023-TOOL-05-03: “Integrated, multi-scale computational models of patient patho-physiology (‘virtual twins’) for personalised disease management”, which had a predominant focus on disease management, and focus on high-potential multi-disciplinary approaches at greater complexity (multiscale, multiorgan, longitudinal), strengthening their deployment in health and care, including the integration into care pathways and links with other decision support tools.
Read the full text
The proposals should address all the following activities:
• Select clinical use cases to deliver multi-disciplinary, high impact solutions requiring multi-organ, multi-scale approaches to modelling complex pathophysiology over time, as a basis from where prevention and diagnosis of diseases with high morbidity and mortality could be enhanced. Proposals can put forward use cases in any areas of high disease burden; examples include co-morbidities, chronic cardiovascular conditions, infection and (auto)immunity, inflammation and cancer, diabetes and related conditions, rare diseases, degenerative diseases (including their interaction with mental health conditions), the exposome and its impact on human health and disease.
• Building on current approaches, standards, data repositories (e.g. biobanks, environmental data, others) and modelling assets (e.g. those of the EDITH CSA [3] and the Platform for Advanced VHT Models [4] ), and new data if relevant, design, develop, extend and validate multi-organ, multi-scale, dynamic computational models that accurately simulate a person’s health and disease states, as necessary.
• Evaluate, select, extend and validate diverse modelling methodologies, resulting in integrated, advanced, interoperable, patient-specific VHT models that can integrate diverse data sources and methodologies, addressing the chosen clinical use case requirements. Methodologies may include and are not limited to biophysics-based modelling, artificial intelligence (AI) that should be interpretable or allow explainability of outcomes, generative AI and in-silico modelling, agent-based and network physiology approaches. Evaluation, selection and extension of these should be documented during the design phase. Availability and integration of the multi-modal data should be documented, and the ethical and sex dimensions be investigated.
• Demonstrate integration of these models with other advanced preventive and diagnostic modalities, tools and techniques enabling integration across pathways.
• Generate evidence, including clinical validation, that…
Who can apply
Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule).
Applicant categories are a starting point. The official call decides eligibility.
Topics
Artificial intelligence, intelligent systems, multi agent systems Basic medicine Big data Clinical medicine Computational biology Computational modelling Machine learning, statistical data processing and applications using signal processing (e.g. speech, image, video) Medical engineering, biomedical engineering and technology Personalised care solutions Personalised interventions Personalised medicine Personalised prevention Artificial intelligence Biophysics-based model Care pathway integration Clinical decision support Clinical validation Computational medicine Digital twin High impact solution
Timing
Single-stage call. Next deadline 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).
How to apply
- Read the full topic on the Funding & Tenders Portal: expected outcome, scope, type of action and the topic conditions, including any country restrictions.
- Register each participating organisation in the Funding & Tenders Portal to get a PIC.
- Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries (Horizon Europe standard rule; Türkiye is associated). Confirm in the topic conditions.
- Prepare Part A (administrative forms and budget, completed in the portal) and Part B (the technical description on the official template for this type of action).
- Submit in the portal before the cut-off time on the deadline day. Late submissions are not accepted.
From the call text
- Who can apply
- Not stated in the call text we hold — check the official page
- Company stage
- Not stated in the call text we hold — check the official page
- Single applicant or consortium
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where applicants must be based
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
- Where to apply
- Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route.
Where these facts come from
| Fact | Value | How we know | Taken from the source |
|---|---|---|---|
| Deadline | 16 September 2027 “Single-stage call. Next deadline 2027-09-16. The portal states the exact cut-off time (EU calls usually close at 17:00 Brussels time).” | official data field | 15 Nov 2026 |
| Amount per applicant | Unknown — not stated in the source we hold | unknown | — |
| Total budget | €39.3 million | official data field | 15 Nov 2026 |
| Funding rate | 100% of eligible costs | programme standard rule | 15 Nov 2026 |
| Who can apply | Consortium of at least 3 independent legal entities from 3 different EU Member States or associated countries, at least one in a Member State (Horizon Europe standard rule). | programme standard rule | 15 Nov 2026 |
| Where to apply | Read the topic conditions on the EU Funding & Tenders Portal for eligible countries, consortium requirements, budget and the application route. | read from the official text | 15 Nov 2026 |
Official sources
Facts on this page come from the funder’s official data, taken on 14 Nov 2026. The funder's own documents, including later amendments, always take precedence.
More from Horizon Europe
Horizon Europe European Union
Next-Generation QKD Systems
This action will strengthen Europe's strategic autonomy in quantum-secure communications by advancing core QKD technologies and integration capabilities. Expected results…
Horizon Europe European Union
Quantum Experimental Pilot Lines for Quantum Technologies
This action will strengthen Europe's leadership and strategic autonomy in quantum technologies by advancing experimental pilot line capacities as a vital stepping stone t…
Horizon Europe European Union
Quantum-Testing Infrastructure for Quantum Technologies
This action will establish a pan-European open-access testing and experimentation infrastructure for quantum technologies, enabling systematic validation and certificatio…
Horizon Europe European Union
Superconducting Platform Technologies
This action will consolidate Europe’s position in superconducting quantum computing through: • Establishment of a full-stack superconducting quantum computer aiming at 1.…